Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
These companies are creating FDA-cleared apps that actually treat diseases. It's a whole new category of medicine where code itself becomes the treatment—potentially reaching millions of patients at a fraction of traditional costs.
The big breakthrough? Insurance providers are increasingly willing to reimburse for these digital therapies. This payment validation could trigger explosive growth as these treatments become mainstream healthcare options.
We're just at the beginning of software-as-medicine. With chronic diseases, mental health conditions, and preventative care all being targeted, these companies are pioneering what could become a multi-billion dollar healthcare category.
Digital therapeutics represent a fundamental shift in healthcare delivery. These clinically-validated software programs are designed to prevent, manage, or treat medical conditions without traditional drugs or devices. As healthcare embraces technology, these scalable solutions promise better patient outcomes at lower costs.
This is an emerging, high-growth sector with significant potential but also substantial risk. Insurance reimbursement is the critical catalyst for widespread adoption. Companies range from pure-play digital therapeutics developers to larger telehealth platforms incorporating these technologies into broader offerings.
We've selected companies directly involved in creating or delivering software-based medical treatments. This includes dedicated digital therapeutics developers, telehealth platforms enabling digital prescriptions, and companies creating complementary technologies that support this emerging ecosystem.
Summary of total market capitalisation and constituent breakdown for the Digital Therapeutics & Prescription Apps basket.
DRIO: $51.25M
GDRX: $1.35B
TDOC: $1.53B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
TELADOC HEALTH INC
TDOC
Current Price
$6.59
A leader in virtual healthcare, it offers a wide range of services including chronic condition management and mental health support through its digita...
A leader in virtual healthcare, it offers a wide range of services including chronic condition management and mental health support through its digital platform.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+111.00%
On average, analysts expect assets in this group to grow 111% over the next year.
9 of 13 assets in this group are rated Buy by professional analysts.
